See more : Medra Corporation (MDRA) Income Statement Analysis – Financial Results
Complete financial analysis of Biora Therapeutics, Inc. (BIOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biora Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Consilium Acquisition Corp I, Ltd. (CSLMU) Income Statement Analysis – Financial Results
- Altair Engineering Inc. (ALTR) Income Statement Analysis – Financial Results
- Advanced Info Service Public Company Limited (ADVANC-R.BK) Income Statement Analysis – Financial Results
- Genting Plantations Berhad (2291.KL) Income Statement Analysis – Financial Results
- Bushveld Minerals Limited (BSHVF) Income Statement Analysis – Financial Results
Biora Therapeutics, Inc. (BIOR)
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M | 127.97M |
Cost of Revenue | 0.00 | 907.00K | 1.44M | 93.43M | 100.49M | 92.08M |
Gross Profit | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M | 35.90M |
Gross Profit Ratio | 100.00% | -197.38% | -15.24% | -25.73% | 30.21% | 28.05% |
Research & Development | 29.84M | 24.05M | 45.79M | 47.74M | 63.40M | 48.71M |
General & Administrative | 0.00 | 0.00 | 68.54M | 75.44M | 61.32M | 51.24M |
Selling & Marketing | 0.00 | 0.00 | 4.76M | 52.89M | 58.89M | 50.19M |
SG&A | 37.31M | 38.04M | 73.30M | 128.33M | 120.21M | 101.43M |
Other Expenses | 0.00 | 2.62M | 5.99M | -25.08M | 0.00 | 0.00 |
Operating Expenses | 67.15M | 62.09M | 119.08M | 176.07M | 183.61M | 150.14M |
Cost & Expenses | 67.15M | 62.09M | 119.08M | 269.50M | 284.10M | 242.21M |
Interest Income | 0.00 | 10.99M | 12.64M | 9.92M | 575.00K | 1.80M |
Interest Expense | 9.82M | 10.99M | 12.64M | 34.87M | 9.20M | 9.09M |
Depreciation & Amortization | 555.00K | 907.00K | 1.44M | 1.44M | 4.60M | 4.60M |
EBITDA | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M | -110.17M |
EBITDA Ratio | -2,851,350.00% | -19,398.03% | -5,106.66% | -262.66% | -92.51% | -84.93% |
Operating Income | -67.14M | -61.78M | -117.84M | -195.19M | -140.12M | -114.24M |
Operating Income Ratio | -1,678,575.00% | -20,256.07% | -9,449.64% | -262.66% | -97.31% | -89.27% |
Total Other Income/Expenses | -57.28M | 12.53M | -60.80M | -35.00M | -8.62M | -9.62M |
Income Before Tax | -124.42M | -49.25M | -178.64M | -230.06M | -148.74M | -123.86M |
Income Before Tax Ratio | -3,110,600.00% | -16,147.54% | -14,325.58% | -309.58% | -103.30% | -96.78% |
Income Tax Expense | -90.00K | -420.00K | -119.00K | -37.53M | -706.00K | 5.25M |
Net Income | -124.12M | -48.83M | -178.52M | -192.53M | -148.04M | -129.11M |
Net Income Ratio | -3,102,875.00% | -16,009.84% | -14,316.04% | -259.08% | -102.81% | -100.88% |
EPS | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
EPS Diluted | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
Weighted Avg Shares Out | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Weighted Avg Shares Out (Dil) | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Biora Therapeutics' (BIOR) CEO Adi Mohanty on Q1 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports